A Review of DNA Vaccines Against Influenza

Leo Yi Yang Lee, Leonard Izzard, Aeron C Hurt, Leo Yi Yang Lee, Leonard Izzard, Aeron C Hurt

Abstract

The challenges of effective vaccination against influenza are gaining more mainstream attention, as recent influenza seasons have reported low efficacy in annual vaccination programs worldwide. Combined with the potential emergence of novel influenza viruses resulting in a pandemic, the need for effective alternatives to egg-produced conventional vaccines has been made increasingly clear. DNA vaccines against influenza have been in development since the 1990s, but the initial excitement over success in murine model trials has been tempered by comparatively poor performance in larger animal models. In the intervening years, much progress has been made to refine the DNA vaccine platform-the rational design of antigens and expression vectors, the development of novel vaccine adjuvants, and the employment of innovative gene delivery methods. This review discusses how these advances have been applied in recent efforts to develop an effective influenza DNA vaccine.

Keywords: DNA vaccine; adjuvant; hemagglutinin; immunization; influenza.

Figures

Figure 1
Figure 1
Key factors considered in the design, formulation, and inoculation of DNA vaccines to improve in vivo transfection efficiency and antigen immunogenicity.

References

    1. WHO. Influenza (Seasonal) – Fact Sheet. Geneva: World Health Organisation Media Centre; (2018). Available from: (Accessed: April 17, 2018).
    1. Sullivan SG, Chilver MB, Carville KS, Deng YM, Grant KA, Higgins G, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill (2017) 22(43):17-00707.10.2807/1560-7917.ES.2017.22.43.17-00707
    1. Flannery B, Chung JR, Belongia EA, Mclean HQ, Gaglani M, Murthy K, et al. Interim estimates of 2017–18 seasonal influenza vaccine effectiveness – United States, February 2018. MMWR Morb Mortal Wkly Rep (2018) 67:180–5.10.15585/mmwr.mm6706a2
    1. Dos Santos G, Neumeier E, Bekkat-Berkani R. Influenza: can we cope better with the unpredictable? Hum Vaccin Immunother (2016) 12:699–708.10.1080/21645515.2015.1086047
    1. Bruffaerts N, Huygen K, Romano M. DNA vaccines against tuberculosis. Expert Opin Biol Ther (2014) 14:1801–13.10.1517/14712598.2014.951630
    1. Mann JF, Mckay PF, Fiserova A, Klein K, Cope A, Rogers P, et al. Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes. J Virol (2014) 88:6959–69.10.1128/JVI.00183-14
    1. Yang B, Jeang J, Yang A, Wu TC, Hung C-F. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother (2014) 10:3153–64.10.4161/21645515.2014.980686
    1. Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine (2008) 26:D41–4.10.1016/j.vaccine.2008.07.043
    1. Stachyra A, Gora-Sochacka A, Sirko A. DNA vaccines against influenza. Acta Biochim Pol (2014) 61:515–22.
    1. Williams JA. Vector design for improved DNA vaccine efficacy, safety and production. Vaccines (Basel) (2013) 1:225–49.10.3390/vaccines1030225
    1. Xenopoulos A, Pattnaik P. Production and purification of plasmid DNA vaccines: is there scope for further innovation? Expert Rev Vaccines (2014) 13:1537–51.10.1586/14760584.2014.968556
    1. Gerdts V, Wilson HL, Meurens F, Van Drunen Littel-Van Den Hurk S, Wilson D, Walker S, et al. Large animal models for vaccine development and testing. ILAR J (2015) 56:53–62.10.1093/ilar/ilv009
    1. Porter KR, Raviprakash K. DNA vaccine delivery and improved immunogenicity. Curr Issues Mol Biol (2017) 22:129–38.10.21775/cimb.022.129
    1. van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J. Animal models in influenza vaccine testing. Expert Rev Vaccines (2008) 7:783.10.1586/14760584.7.6.783
    1. Bodewes R, Rimmelzwaan GF, Osterhaus ADME. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines (2010) 9:59–72.10.1586/erv.09.148
    1. Munster VJ, De Wit E, Van Den Brand JMA, Herfst S, Schrauwen EJA, Bestebroer TM, et al. Pathogenesis and transmission of Swine-Origin 2009 A(H1N1) influenza virus in ferrets. Science (2009) 325:481–3.10.1126/science.1177127
    1. Belser JA, Katz JM, Tumpey TM. The ferret as a model organism to study influenza A virus infection. Dis Model Mech (2011) 4:575–9.10.1242/dmm.007823
    1. Rimmelzwaan GF, Katz JM. Immune responses to infection with H5N1 influenza virus. Virus Res (2013) 178:44–52.10.1016/j.virusres.2013.05.011
    1. Grunwald T, Ulbert S. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. Clin Exp Vaccine Res (2015) 4:1–10.10.7774/cevr.2015.4.1.1
    1. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines (2016) 15:313–29.10.1586/14760584.2016.1124762
    1. Wong S-S, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev (2013) 26:476–92.10.1128/CMR.00097-12
    1. Schultz-Cherry S, Jones JC. Influenza vaccines: the good, the bad, and the eggs. Adv Virus Res (2010) 77:63–84.10.1016/B978-0-12-385034-8.00003-X
    1. Kempe A, Daley MF, Stokley S, Crane LA, Beaty BL, Barrow J, et al. Impact of a severe influenza vaccine shortage on primary care practice. Am J Prev Med (2007) 33:486–91.10.1016/j.amepre.2007.07.038
    1. Uscher-Pines L, Barnett DJ, Sapsin JW, Bishai DM, Balicer RD. A systematic analysis of influenza vaccine shortage policies. Public Health (2008) 122:183–91.10.1016/j.puhe.2007.06.005
    1. Tewawong N, Prachayangprecha S, Vichiwattana P, Korkong S, Klinfueng S, Vongpunsawad S, et al. Assessing antigenic drift of seasonal influenza A(H3N2) and A(H1N1)pdm09 viruses. PLoS One (2015) 10:e0139958.10.1371/journal.pone.0139958
    1. Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, et al. 2014–2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis (2016) 63:1564–73.10.1093/cid/ciw635
    1. Parker L, Wharton SA, Martin SR, Cross K, Lin Y, Liu Y, et al. Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. J Gen Virol (2016) 97:1333–44.10.1099/jgv.0.000457
    1. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 18:765–77.10.1016/S0264-410X(99)00271-6
    1. Grodeland G, Fredriksen AB, Løset GÅ, Vikse E, Fugger L, Bogen B. Antigen targeting to human HLA class II molecules increases efficacy of DNA vaccination. J Immunol (2016) 197:3575–85.10.4049/jimmunol.1600893
    1. Rush C, Mitchell T, Garside P. Efficient priming of CD4+ and CD8+ T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways. J Immunol (2002) 169:4951.10.4049/jimmunol.169.9.4951
    1. Wiersma LCM, Rimmelzwaan GF, De Vries RD. Developing universal influenza vaccines: hitting the nail, not just on the head. Vaccines (Basel) (2015) 3:239–62.10.3390/vaccines3020239
    1. Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine (1993) 11:957–60.10.1016/0264-410X(93)90385-B
    1. Robinson HL, Boyle CA, Feltquate DM, Morin MJ, Santoro JC, Webster RG. DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J Infect Dis (1997) 176:S50–5.10.1086/514176
    1. Barría MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis (2013) 207:115–24.10.1093/infdis/jis641
    1. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med (2013) 19:1305.10.1038/nm.3350
    1. Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: shifting to better vaccines. Vaccine (2016) 34:2926–33.10.1016/j.vaccine.2016.03.085
    1. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 259:1745–9.10.1126/science.8456302
    1. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis (2007) 13:426–35.10.3201/eid1303.061125
    1. Wang W, Li R, Deng Y, Lu N, Chen H, Meng X, et al. Protective efficacy of the conserved NP, PB1, and M1 proteins as immunogens in DNA- and vaccinia virus-based universal influenza A virus vaccines in mice. Clin Vaccine Immunol (2015) 22:618–30.10.1128/CVI.00091-15
    1. Bragstad K, Vinner L, Hansen MS, Nielsen J, Fomsgaard A. A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection. Vaccine (2013) 31:2281–8.10.1016/j.vaccine.2013.02.061
    1. Price GE, Soboleski MR, Lo C-Y, Misplon JA, Pappas C, Houser KV, et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine (2009) 27:6512–21.10.1016/j.vaccine.2009.08.053
    1. Koday MT, Leonard JA, Munson P, Forero A, Koday M, Bratt DL, et al. Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates. PLoS One (2017) 12:e0189780.10.1371/journal.pone.0189780
    1. Park KS, Seo YB, Lee JY, Im SJ, Seo SH, Song MS, et al. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Vaccine (2011) 29:5481–7.10.1016/j.vaccine.2011.05.062
    1. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 1(1):e00018–10.10.1128/mBio.00018-10
    1. Wang B, Yu H, Yang FR, Huang M, Ma JH, Tong GZ. Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin. Virol J (2012) 9:127.10.1186/1743-422X-9-127
    1. Choi EJ, Lee HS, Noh JY, Song JY, Cheong HJ, Shin OS, et al. Humoral and cellular immunogenicity induced by avian influenza A (H7N9) DNA vaccine in mice. Infect Chemother (2017) 49:117–22.10.3947/ic.2017.49.2.117
    1. Yan J, Morrow MP, Chu JS, Racine T, Reed CC, Khan AS, et al. Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine. Vaccine (2018) 36(22):3079–89.10.1016/j.vaccine.2017.09.086
    1. Chen M-W, Cheng T-JR, Huang Y, Jan J-T, Ma S-H, Yu AL, et al. A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA (2008) 105:13538–43.10.1073/pnas.0806901105
    1. Huber VC, Thomas PG, Mccullers JA. A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine (2009) 27:1192–200.10.1016/j.vaccine.2008.12.023
    1. Rao S, Kong WP, Wei CJ, Yang ZY, Nason M, Styles D, et al. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One (2008) 3:e2432.10.1371/journal.pone.0002432
    1. Wang S, Taaffe J, Parker C, Solorzano A, Cao H, Garcia-Sastre A, et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol (2006) 80:11628–37.10.1128/JVI.01065-06
    1. Tenbusch M, Grunwald T, Niezold T, Bonsmann MSG, Hannaman D, Norley S, et al. Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4+ T-cell responses and immune effector mechanisms following DNA electroporation in mice. Vaccine (2010) 28:3273–7.10.1016/j.vaccine.2010.02.090
    1. Stachyra A, Redkiewicz P, Kosson P, Protasiuk A, Gora-Sochacka A, Kudla G, et al. Codon optimization of antigen coding sequences improves the immune potential of DNA vaccines against avian influenza virus H5N1 in mice and chickens. Virol J (2016) 13:143.10.1186/s12985-016-0599-y
    1. Jiang Y, Yu K, Zhang H, Zhang P, Li C, Tian G, et al. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector. Antiviral Res (2007) 75:234–41.10.1016/j.antiviral.2007.03.009
    1. Wang S, Hackett A, Jia N, Zhang C, Zhang L, Parker C, et al. Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One (2011) 6:e28757.10.1371/journal.pone.0028757
    1. Andersen TK, Zhou F, Cox R, Bogen B, Grødeland G. A DNA vaccine that targets hemagglutinin to antigen presenting cells protects mice against H7 influenza. J Virol (2017) 91(23):e01340–17.10.1128/JVI.01340-17
    1. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science (1990) 247:1465–8.10.1126/science.1690918
    1. Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum Vaccin (2011) 7:811–27.10.4161/hv.7.8.16274
    1. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol (2000) 164:4635–40.10.4049/jimmunol.164.9.4635
    1. Lee SW, Youn JW, Seong BL, Sung YC. IL-6 induces long-term protective immunity against a lethal challenge of influenza virus. Vaccine (1999) 17:490–6.10.1016/S0264-410X(98)00223-0
    1. Yager EJ, Stagnar C, Gopalakrishnan R, Fuller JT, Fuller DH. Optimizing particle-mediated epidermal delivery of an influenza DNA vaccine in ferrets. Methods Mol Biol (2013) 940:223–37.10.1007/978-1-62703-110-3_19
    1. Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol (2012) 19:1792–7.10.1128/CVI.05663-11
    1. Graham BS, Enama ME, Nason MC, Gordon IJ, Peel SA, Ledgerwood JE, et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One (2013) 8:e59340.10.1371/journal.pone.0059340
    1. Crank MC, Gordon IJ, Yamshchikov GV, Sitar S, Hu Z, Enama ME, et al. Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS One (2015) 10:e0123969.10.1371/journal.pone.0123969
    1. Raphael AP, Prow TW, Crichton ML, Chen X, Fernando GJ, Kendall MA. Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small (2010) 6:1785–93.10.1002/smll.201000326
    1. Kim YC, Song JM, Lipatov AS, Choi SO, Lee JW, Donis RO, et al. Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm (2012) 81:239–47.10.1016/j.ejpb.2012.03.010
    1. Fernando GJ, Zhang J, Ng HI, Haigh OL, Yukiko SR, Kendall MA. Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(+) T cell responses. J Control Release (2016) 237:35–41.10.1016/j.jconrel.2016.06.045
    1. Song J-M, Kim Y-C, Eunju O, Compans RW, Prausnitz MR, Kang S-M. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther (2012) 20:1472–80.10.1038/mt.2012.69
    1. Smith TRF, Schultheis K, Kiosses WB, Amante DH, Mendoza JM, Stone JC, et al. DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Mol Ther Methods Clin Dev (2014) 1:14054.10.1038/mtm.2014.54
    1. Hartikka J, Sukhu L, Buchner C, Hazard D, Bozoukova V, Margalith M, et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther (2001) 4:407–15.10.1006/mthe.2001.0483
    1. Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, et al. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother (2013) 9:2246–52.10.4161/hv.24702
    1. Schultheis K, Schaefer H, Yung BS, Oh J, Muthumani K, Humeau L, et al. Characterization of guinea pig T cell responses elicited after EP-assisted delivery of DNA vaccines to the skin. Vaccine (2017) 35:61–70.10.1016/j.vaccine.2016.11.052
    1. Borggren M, Nielsen J, Bragstad K, Karlsson I, Krog JS, Williams JA, et al. Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans. Hum Vaccin Immunother (2015) 11:1983–90.10.1080/21645515.2015.1011987
    1. Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 83:4624–30.10.1128/JVI.02335-08
    1. Zanin M, Baviskar P, Webster R, Webby R. The interaction between respiratory pathogens and mucus. Cell Host Microbe (2016) 19:159–68.10.1016/j.chom.2016.01.001
    1. Gould VMW, Francis JN, Anderson KJ, Georges B, Cope AV, Tregoning JS. Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Front Microbiol (2017) 8:900.10.3389/fmicb.2017.00900
    1. Zaman M, Chandrudu S, Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res (2013) 3:100–9.10.1007/s13346-012-0085-z
    1. Loh L, Wang Z, Sant S, Koutsakos M, Jegaskanda S, Corbett AJ, et al. Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation. Proc Natl Acad Sci U S A (2016) 113:10133–8.10.1073/pnas.1610750113
    1. Xu Y, Yuen PW, Lam JK. Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives. Pharmaceutics (2014) 6:378–415.10.3390/pharmaceutics6030378
    1. Savelkoul HF, Ferro VA, Strioga MM, Schijns VE. Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines (Basel) (2015) 3:148–71.10.3390/vaccines3010148
    1. Torrieri-Dramard L, Lambrecht B, Ferreira HL, Van Den Berg T, Klatzmann D, Bellier B. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol Ther (2011) 19:602–11.10.1038/mt.2010.222
    1. Rajapaksa AE, Ho JJ, Qi A, Bischof R, Nguyen T-H, Tate M, et al. Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respir Res (2014) 15:60–60.10.1186/1465-9921-15-60
    1. He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother (2015) 11:477–88.10.1080/21645515.2014.1004026
    1. Ulmer JB, Dewitt CM, Chastain M, Friedman A, Donnelly JJ, Mcclements WL, et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine (1999) 18:18–28.10.1016/S0264-410X(99)00151-6
    1. Li L, Petrovsky N. Molecular adjuvants for DNA vaccines. Curr Issues Mol Biol (2017) 22:17–40.10.21775/cimb.022.017
    1. Silver JS, Hunter CA. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol (2010) 88:1145–56.10.1189/jlb.0410217
    1. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci (2012) 8:1237–47.10.7150/ijbs.4989
    1. Larsen DL, Dybdahl-Sissoko N, Mcgregor MW, Drape R, Neumann V, Swain WF, et al. Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice. J Virol (1998) 72:1704–8.
    1. Fagone P, Shedlock DJ, Bao H, Kawalekar OU, Yan J, Gupta D, et al. Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther (2011) 18:1070–7.10.1038/gt.2011.59
    1. Loudon PT, Yager EJ, Lynch DT, Narendran A, Stagnar C, Franchini AM, et al. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One (2010) 5:e11021.10.1371/journal.pone.0011021
    1. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, Van Drunen Littel-Van Den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine (2003) 21:649–58.10.1016/S0264-410X(02)00574-1
    1. Hoekstra D, Rejman J, Wasungu L, Shi F, Zuhorn I. Gene delivery by cationic lipids: in and out of an endosome. Biochem Soc Trans (2007) 35:68–71.10.1042/BST0350068
    1. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin (2007) 3:157–64.10.4161/hv.3.5.4175
    1. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis (2008) 197:1643–52.10.1086/588431
    1. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine (2010) 28:2565–72.10.1016/j.vaccine.2010.01.029
    1. Wang G, Pan L, Zhang Y, Wang Y, Zhang Z, Lu J, et al. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS One (2011) 6:e27605.10.1371/journal.pone.0027605
    1. Seok H, Noh JY, Lee DY, Kim SJ, Song CS, Kim YC. Effective humoral immune response from a H1N1 DNA vaccine delivered to the skin by microneedles coated with PLGA-based cationic nanoparticles. J Control Release (2017) 265:66–74.10.1016/j.jconrel.2017.04.027
    1. Sawaengsak C, Mori Y, Yamanishi K, Srimanote P, Chaicumpa W, Mitrevej A, et al. Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes. Int J Pharm (2014) 473:113–25.10.1016/j.ijpharm.2014.07.005
    1. Khurana S, Coyle EM, Manischewitz J, King LR, Ishioka G, Alexander J, et al. Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization. PLoS One (2015) 10:e0115476.10.1371/journal.pone.0115476
    1. Wu Y, Yang D, Xu B, Liang W, Sui J, Chen Y, et al. Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice. Antiviral Res (2017) 147:29–36.10.1016/j.antiviral.2017.09.009
    1. Elaish M, Ngunjiri JM, Ali A, Xia M, Ibrahim M, Jang H, et al. Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens. PLoS One (2017) 12:e0171174.10.1371/journal.pone.0171174
    1. Zhu W, Pewin W, Wang C, Luo Y, Gonzalez GX, Mohan T, et al. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines. J Control Release (2017) 261:1–9.10.1016/j.jconrel.2017.06.017
    1. Wang S, Parker C, Taaffe J, Solórzano A, García-Sastre A, Lu S. Heterologous HA DNA vaccine prime – inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine (2008) 26:3626–33.10.1016/j.vaccine.2008.04.073
    1. Suguitan AL, Jr, Cheng X, Wang W, Wang S, Jin H, Lu S. Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One (2011) 6:e21942.10.1371/journal.pone.0021942
    1. Stachyra A, Pietrzak M, Macioła A, Protasiuk A, Olszewska M, Śmietanka K, et al. A prime/boost vaccination with HA DNA and Pichia-produced HA protein elicits a strong humoral response in chickens against H5N1. Virus Res (2017) 232:41–7.10.1016/j.virusres.2017.01.025
    1. Ledgerwood JE, Bellamy AR, Belshe R, Bernstein DI, Edupuganti S, Patel SM, et al. DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. PLoS One (2015) 10:e0125914.10.1371/journal.pone.0125914
    1. Ledgerwood JE, Hu Z, Costner P, Yamshchikov G, Enama ME, Plummer S, et al. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemp Clin Trials (2015) 44:112–8.10.1016/j.cct.2015.08.006
    1. Chang H, Huang C, Wu J, Fang F, Zhang W, Wang F, et al. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus. Virol J (2010) 7:197–197.10.1186/1743-422X-7-197
    1. Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis (2013) 208:418–22.10.1093/infdis/jit180
    1. DeZure AD, Coates EE, Hu Z, Yamshchikov GV, Zephir KL, Enama ME, et al. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ Vaccines (2017) 2:15.10.1038/s41541-017-0016-6
    1. Myhr AI. DNA vaccines: regulatory considerations and safety aspects. Curr Issues Mol Biol (2017) 22:79–88.10.21775/cimb.022.079
    1. AgriLabs. First DNA Vaccine Licensed for Chickens. PR Newswire: Cision; (2017). Available: (Accessed: January 14, 2018).
    1. Takeda A, Igarashi H, Nakamura H, Kano M, Iida A, Hirata T, et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J Virol (2003) 77:9710–5.10.1128/JVI.77.17.9710-9715.2003
    1. Yu S, Feng X, Shu T, Matano T, Hasegawa M, Wang X, et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine (2008) 26:6124–31.10.1016/j.vaccine.2008.09.017
    1. Grubor-Bauk B, Yu W, Wijesundara D, Gummow J, Garrod T, Brennan AJ, et al. Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Ther (2016) 23:26–37.10.1038/gt.2015.86
    1. Lee H, Jeong M, Oh J, Cho Y, Shen X, Stone J, et al. Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of hepatitis C virus infection. Sci Rep (2017) 7:43531.10.1038/srep43531
    1. Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet (2017) 391:552–62.10.1016/S0140-6736(17)33105-7
    1. Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine – preliminary report. N Engl J Med (2017).10.1056/NEJMoa1708120

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever